You are here

Article Text

Article menu
Download PDFPDF
Short report
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer
  1. C Cybulski1,
  2. D Wokołorczyk1,
  3. T Huzarski1,
  4. T Byrski1,
  5. J Gronwald1,
  6. B Górski1,
  7. T Dębniak1,
  8. B Masojć1,
  9. A Jakubowska1,
  10. B Gliniewicz2,
  11. A Sikorski2,
  12. M Stawicka3,
  13. D Godlewski3,
  14. Z Kwias4,
  15. A Antczak4,
  16. K Krajka5,
  17. W Lauer5,
  18. M Sosnowski6,
  19. P Sikorska-Radek7,
  20. K Bar8,
  21. R Klijer8,
  22. R Zdrojowy9,
  23. B Małkiewicz9,
  24. A Borkowski10,
  25. T Borkowski10,
  26. M Szwiec11,
  27. S A Narod12,
  28. J Lubiński1
  1. 1International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
  2. 2Clinic of Urology, Pomeranian Medical University, Szczecin
  3. 3Cancer Prevention and Epidemiology Center, Poznan, Poland
  4. 4Clinic of Urology, Medical Academy, Poznan
  5. 5Clinic of Urology, Medical Academy, Gdansk, Poland
  6. 6Clinic of Urology, Medical Academy, Łódź, Poland
  7. 7Clinic of Urology Regional Hospital, Łódź
  8. 8Clinic of Urology, Medical Academy, Lublin, Poland
  9. 9Clinic of Urology, Medical Academy, Wrocław, Poland
  10. 10Clinic of Urology, Medical Academy, Warszawa, Poland
  11. 11Regional Oncology Hospital, Olsztyn, Poland
  12. 12Centre for Research on Women’s Health, Toronto, Ontario, Canada
  1. Correspondence to:
 C Cybulski
 Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul Połabska 4, 70-115 Szczecin, Poland; cezarycy{at}sci.pam.szczecin.pl

Abstract

Background: Germline mutations in the Chek2 kinase gene (CHEK2) have been associated with a range of cancer types. Recently, a large deletion of exons 9 and 10 of CHEK2 was identified in several unrelated patients with breast cancer of Czech or Slovak origin. The geographical and ethnic extent of this founder allele has not yet been determined.

Participants and methods: We assayed for the presence of this deletion, and of three other CHEK2 founder mutations, in 1864 patients with prostate cancer and 5496 controls from Poland.

Results: The deletion was detected in 24 of 5496 (0.4%) controls from the general population, and is the most common CHEK2 truncating founder allele in Polish patients. The deletion was identified in 15 of 1864 (0.8%) men with unselected prostate cancer (OR 1.9; 95% CI 0.97 to 3.5; p = 0.09) and in 4 of 249 men with familial prostate cancer (OR 3.7; 95% CI 1.3 to 10.8; p = 0.03). These ORs were similar to those associated with the other truncating mutations (IVS2+1G→A, 1100delC).

Conclusion: A large deletion of exons 9 and 10 of CHEK2 confers an increased risk of prostate cancer in Polish men. The del5395 founder deletion might be present in other Slavic populations, including Ukraine, Belarus, Russia, Baltic and Balkan countries. It will be of interest to see to what extent this deletion is responsible for the burden of prostate cancer in other populations.

  • CHEK2, Chek2 kinase gene
  • PCR, polymerase chain reaction

https://doi.org/10.1136/jmg.2006.044974

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None.

    • Ethical approval: This study was approved by the Ethics Committee of Pomeranian Medical University, Szczecin, Poland.